Biodexa shares surge 51.58% after-hours after partnering with Syngene to manufacture MTX240 GMP clinical trial supplies.

Biodexa Pharmaceuticals surged 51.58% in after-hours trading following the announcement of a partnership with Syngene International to manufacture MTX240 GMP clinical trial supplies. The deal covers both the active pharmaceutical ingredient and dosage form, marking a key step toward advancing the company’s oncology pipeline. This follows Biodexa’s recent licensing of MTX240 from Otsuka and comes after Syngene successfully produced the company’s tolimidone program on time and on budget. The partnership accelerates the path to an IND filing and a Phase 1b/2a trial, positioning Biodexa to advance its novel molecular glue therapy for GIST patients resistant to existing treatments.